Initial Report of a Phase II Trial of Weekly Cetuximab, CBDCA, Paclitaxel, and Daily RT in Patients with Locally Advanced SCCHN
M. Suntharalingam(University of Maryland, Baltimore), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Randall S. Taylor(University of Maryland, Baltimore), R.A. Ord(University of Maryland, Baltimore), Julius Wolf(University of Maryland, Baltimore), K. Cullen(University of Maryland, Baltimore), Ann B. Zimrin(University of Maryland, Baltimore)
International Journal of Radiation Oncology*Biology*Physics
September 13, 2007
Cited by 4
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|548
618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
|The Journal of Urology|2005|387